Table 2. Association of Screening With Prostate Cancer Incidence Overall and Prostate Cancer–Specific Mortality Among Statin Users and Nonusers by 1 or More or No Opportunistic Prostate-Specific Antigen–Tests Takena.
| Statin use status | PCa incidence overall by study group (Ref = control group) | PCa mortality by study group (Ref = control group) | ||||||
|---|---|---|---|---|---|---|---|---|
| One or more opportunistic PSA tests | No opportunistic PSA tests | One or more opportunistic PSA tests | No opportunistic PSA tests | |||||
| RR (95% CI) | P value for interaction | RR (95% CI) | P value for interaction | RR (95% CI) | P value for interaction | RR (95% CI) | P value for interaction | |
| Nonuser of statins | 1.72 (1.39-2.12) | NA | 1.28 (1.21-1.35) | NA | 1.39 (0.71-2.73) | NA | 0.83 (0.70-0.99) | NA |
| Any use of statins | 1.66 (1.20-2.30) | .82 | 0.99 (0.92-1.07) | <.001 | 3.87 (1.23-12.1) | .13 | 0.86 (0.64-1.17) | .86 |
| <0.65 defined dose/d | 1.95 (0.20-3.16) | .65 | 0.92 (0.81-1.04) | <.001 | 5.94 (1.26-28.0) | .09 | 0.65 (0.39-1.06) | .33 |
| 0.65-1.08 defined dose/d | 1.88 (1.01-3.50) | .82 | 1.07 (0.93-1.22) | .01 | NAb | NA | 0.88 (0.53-1.45) | .87 |
| >1.08 defined dose/d | 1.22 (0.65-2.29) | .27 | 1.00 (0.86-1.16) | .003 | 0.62 (0.06-6.88) | .55 | 1.29 (0.71-2.34) | .16 |
Abbreviations: NA, not available; PCa, prostate cancer; PSA, prostate-specific antigen; Ref, reference; RR, rate ratio.
a
Study population of 78 606 men from the Finnish Randomized Study of Screening for Prostate Cancer.
b
Convergence not achieved.